ArticleCJC open2026
Do Medications Actually Help in Patients with Postural Orthostatic Tachycardia Syndrome?: A Qualitative Study.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder associated with debilitating symptoms. No medications have been approved for treatment, and patients commonly use off-label medications to treat symptoms. The hemodynamic implications of certain medication use have been examined, but patient experiences with taking off-label medications are underreported. Methods: A qualitative descriptive study was conducted with 13 patients (all women; aged 38 ± 13 years) diagnosed with POTS who had taken off-label medications for their symptoms. Semistructured video interviews were conducted to explore how they experienced and perceived their medication use. Interviews were recorded, transcribed, and analyzed using conventional content analysis. Results: Most patients described medications as being beneficial and life-altering, re-enabling basic activities, work, exercise, and social engagement. All patients intended to continue therapy. Side effects were common but generally manageable. Propranolol frequently was associated with fatigue and hypotension. Ivabradine often caused transient early headaches and visual symptoms that subsided. Dosing frequency was largely acceptable. Major barriers included the following: medication cost, especially for ivabradine when patients were not insured; limited clinician awareness of POTS; diagnostic delays; and uncertainty about long-term safety. Conclusions: Medications provide meaningful functional improvement for many patients, but treatment burden, financial barriers, and information gaps persist. Care should prioritize individualized, patient-centred prescribing, and shared decision-making. Additional research should compare common medications to increase exposure and evaluate long-term outcomes and access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.